Thursday, 25 May 2017

Today's Headlines

Low Dose Treatment in Ankylosing Spondylitis Still Effective

About one-third of ankylosing spondylitis patients who cut their etanercept (Enbrel) dose in half maintained responses over 4 years, compared with two-thirds who stayed on standard therapy, researchers reported.

NLRP3 Activation in Still's Disease

Adult-onset Still disease (AOSD) is usually regarded as an autoinflammatory disease, largely because of its symptomatology and responsiveness to IL-1 inhibition.  Thus while it is assumed that aberrant NLRP3 inflammasome activity underlies active AOSD, the connection between NLRP3 AOSD has yet to be solidfied.

Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis

The NEJM reports success when using mepolizumab (anti-IL-5 monoclonal antibody) in a 52 week study of patients with eosinophilic granulomatosis with polyangiitis (EGPA).

IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis

The FDA has approved sarilumab (Kevzara), a new IL-6 inhibotor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).

Although approved in Canada in February 2017, the US submission of the sarilumabs BLA was held up by the FDA with a complete response letter and concerns about manufacturing.

Actemra - First FDA Approved Drug for Giant Cell Arteritis

The FDA has approved subcutaneous tocilizumab for use in Giant Cell Arteritis based on the phase III GiACTA study that demonstrated that TCZ with steroids was superior to steroid therapy alone.

BLOG

A 25 year-old female recently diagnosed with seronegative rheumatoid arthritis was started on a T

Patients are labeled as having “difficult RA" when: 1) we are frustrated, 2) it's too late, 3) we've run out of options or 4) the relationship is failing. We see them, but don’t quite know what to do with them.

Historically, syphilis and tuberculosis were the “great masqueraders” in medicine.

My original agreement with Jack was to review a serious scientific book.  However, half way through one, I was bored, so I went to the library. I'm so glad I did, because I came upon two books, written by Ireland-born physician Patrick Taylor, that continued the tale I'd started years ago about Fingal Flahertie O'Reilly.

 

I had dinner about a month ago in Phoenix with Peter Lipsky, an icon in rheumatology and who requires no introduction to my readers, where we discussed a rambling number of topics both rheumatologic (hence, the experience does qualify for a blog!) and non-rheumatologic.
RWCS 2017: Location, Location, Location | A Case of Shoulder Pain After Vaccination
/vef/load/6d0103c13edd9c93424a8990bcd6c292?width=640&height=365

Social

Daily Download

New TNF Inhibitor Biosimilars

RheumNow Live Vote

As biosimilar biologic agents become available, when will you use them?

This month’s Live Vote is being guided by Dr. Artie Kavanaugh and will focus on the rheumatologists' views on biosimilars.

View the Result